This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
500
OLN324 by intravitreal injection at protocol-specified dosing intervals
Aflibercept by intravitreal injection at protocol-specified dosing intervals
Change in BCVA
Change in ETDRS BCVA eye chart letter score from Day 1 to Week 48.
Time frame: Day 1 to Week 48
Mean change in OCT CST
Difference in the mean change from baseline in OCT CST in the Study Eye between the OLN324 arm and the aflibercept arm
Time frame: Day 1 to Week 16
Change in PED thickness
Difference in the mean change from baseline in PED thickness on OCT in the Study Eye between the OLN324 arm and the aflibercept arm
Time frame: Day 1 to Week 16
Percentage of participants without retinal fluid in the central subfield at Week 16
Difference in the percentage of participants with absence of both IRF and SRF in the central subfield of the Study Eye between the OLN324 arm and the aflibercept arm
Time frame: Week 16
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.